{"id":"W4362587019","doi":"10.1016/s1556-0864(23)00423-9","title":"169P Phase I dose escalation trial combining olaparib and thoracic radiation therapy in extensive-stage small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"PharmaMar; Castle Biosciences; Daiichi Sankyo Europe; Exelixis; ViewRay; Novocure; Elekta; Varian Medical Systems; Pfizer; Eli Lilly and Company; AstraZeneca; Accuray; LUNGevity Foundation; MedImmune; Mesothelioma Applied Research Foundation","keywords":"Medicine; Olaparib; Atezolizumab; Internal medicine; Oncology; Dysgeusia; Lung cancer; Adverse effect; Radiation therapy; Urology; Cancer; Gastroenterology; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002100591,0.0001702316,0.0007243949,0.0006539839,0.0001043965,0.0000297173,0.0001069737,0.0001740187,0.00006658629],"category_scores_gemma":[0.0004779737,0.0001352262,0.0001115599,0.0006062808,0.0001025284,0.0001984956,0.00006502087,0.0007012303,0.000004623061],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007301938,"about_ca_system_score_gemma":0.0007975608,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007839344,"about_ca_topic_score_gemma":0.00007626551,"domain_scores_codex":[0.9978498,0.0004625101,0.0006950481,0.0002252952,0.0003926551,0.0003746597],"domain_scores_gemma":[0.998141,0.0005794945,0.0005877678,0.0001474256,0.000360908,0.0001834186],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1520533,0.001151436,0.03416324,0.0004524871,0.000373687,0.001407204,0.005962276,0.0003825821,0.02294344,0.00001300432,0.004617163,0.7764802],"study_design_scores_gemma":[0.4341041,0.05211706,0.3801237,0.002054823,0.001514223,0.0005281356,0.00757385,0.03866141,0.02320354,0.0006369672,0.058315,0.001167155],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863846,0.006118591,0.00007303974,0.005144874,0.000922017,0.0009203047,0.000008493908,0.00002703301,0.0004009966],"genre_scores_gemma":[0.9854091,0.0123677,0.0003285056,0.0003366614,0.000769076,0.00005804333,0.00001046382,0.00002855604,0.0006919105],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7753131,"threshold_uncertainty_score":0.5514364,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07487591896206015,"score_gpt":0.50855599154978,"score_spread":0.4336800725877199,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}